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Abstract 
 
Objectives. To assess the risk of venous thromboembolism in relation to hormone 
therapy by study design, characteristics of hormone therapy and venous 
thromboembolism, and clinical background. 
Design. Systematic review and meta-analysis of observational studies and 
randomized clinical trials identified from Medline. 
Studies reviewed. 8 observational studies and 9 randomised controlled trials. 
Review measures. Homogeneity between studies was analyzed using ² and I² 
statistics. Overall risk was assessed from a fixed-effects or a random-effects model. 
Results. Meta-analysis of observational studies showed that oral but not transdermal 
oestrogen increased the risk of venous thromboembolism. Compared with non-users, 
odds ratios (95 % confidence interval) of first-time venous thromboembolism in 
current users of oral and transdermal oestrogen were 2.5(1.9-3.4) and 1.2(0.9-1.7), 
respectively. Past users of oral oestrogen had similar risk of venous 
thromboembolism to never users. The risk of venous thromboembolism in relation to 
oral oestrogen was higher within the first year of treatment [4.0(2.9-5.7)] for a 
duration less than 1 year, compared to [2.1(1.3-3.8)] for a duration more than 1 year, 
(p<0.05). No striking difference in the risk of venous thromboembolism was observed 
between unopposed and opposed oral oestrogen [2.2(1.6-3.0) and 2.6(2.0-3.2), 
respectively]. Results from nine randomised controlled trials have confirmed the 
increased risk of venous thromboembolism among women using oral oestrogen 
[2.1(1.4-3.1)]. The combination of oral oestrogen use and either thrombogenic 
mutations or obesity further enhanced the risk of venous thromboembolism, whereas 
transdermal oestrogen might not confer additional risk on women at high venous 
thromboembolism risk.  
Conclusion. Oral oestrogen increases the risk of venous thromboembolism, 
especially during the first year of treatment. Transdermal oestrogen may be safer 
with respect to thrombotic risk. More data are required to investigate differences in 
risk across the wide variety of hormone regimens, especially the different types of 
progestogens.
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Introduction 
 
Hormone therapy can improve the quality of life of women with hypo-oestrogenic 
symptoms 1. Despite recent data showing that overall health risks may exceed 
benefits of long-term hormone therapy 2, many women are still prescribed estrogen 
therapy to treat postmenopausal climacteric symptoms. Hormone therapy is also 
effective for preventing osteoporotic fractures among current users 2 3. By contrast, 
harmful effects of hormone therapy include breast cancer and venous 
thromboembolism 4. Furthermore, randomised controlled trials showed that hormone 
therapy might increase the risk of coronary heart disease and stroke 2 5.  
Despite evidence that oral oestrogen activates blood coagulation in postmenopausal 
women 6,  hormone therapy had, until 1996, long been believed to have little effect on 
the risk of venous thromboembolism 7. However, observational studies recently 
showed consistent associations between current use of hormone therapy and an 
increased risk of venous thromboembolism in postmenopausal women 5 w1-w11. These 
findings have been confirmed by randomised controlled trials 5 w12-w20. 
Most previous studies of venous thromboembolism in users of hormone therapy were 
done among women using conjugated equine oestrogens alone or combined with 
medroxyprogesterone acetate 8 9. These results cannot be generalized to other 
regimens of hormone therapy, especially those used in some European countries. 
Recent data have suggested the importance of the route of oestrogen administration 
in determining risk of venous thromboembolism 10. 
The purpose of this review was to estimate the risk of venous thromboembolism 
among hormone therapy users. This quantitative assessment takes into account the 
study design (observational studies or randomized controlled trials) and the 
characteristics of both hormone therapy (route of oestrogen administration, 
unopposed or combined with progestogens, duration of treatment) and venous 
thromboembolism (idiopathic or secondary). 
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Methods 
 
Literature search 
An electronic search of medical literature was carried out on the MEDLINE database 
from 1974 to 2007. Relevant keywords relating to hormone therapy (eg, "estrogen 
replacement" or "oestrogen replacement" or "estrogen" or "estrogen therapy" or 
"oestrogen" or  "oestrogen therapy" or "estrogen replacement therapy" or "oestrogen 
replacement therapy" or "hormone" or "hormone replacement therapy" or "hormone 
therapy" or "hormonal therapy" or "hormonal replacement therapy") were used in 
combination with words relating to venous thromboembolism (eg, "venous 
thrombosis" or "venous thromboembolism" or "thrombosis" or "pulmonary embolism" 
or "embolism" or "emboli") We also identified original articles by back-referencing 
from general reviews published after 1970 7-9 11-17.  
 
Study selection 
We screened all articles identified by key words using Medline Database (n=1890). 
We first excluded publications not in English, not related to the topic, on 
contraception and biological studies. The selected articles (n=111) were reviewed 
and we excluded general reviews and articles which did not assess venous 
thromboembolism risk. Twenty four studies (nine randomised controlled trials w12-w20, 
twelve case-control studies w1-w3 w5-w7 w9-w11 w21-23 and three prospective cohort studies 
w4 w24-w25) were eligible for inclusion in meta-analysis and were assessed for quality. 
 
Quality assessment 
We assessed the quality of randomized controlled trials and observational studies 
separately. Regarding randomized controlled trials, we assessed studies for quality of 
randomization, blinding, reporting of withdrawals, generation of random numbers and 
concealment of allocation. Trials scored one point for each area addressed, therefore 
receiving a score between 0 and 5 (highest level of quality) 18 19. We included in the 
meta-analysis trials which had a score higher or equal to 4 w12-w20 (Table 1). We 
assessed the quality of observational studies using a specific checklist consistent 
with the consensus recommendations by the Meta-analysis Of Observational Studies 
in Epidemiology MOOSE group 20. Case-control studies received a score between 0 
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and 6 (highest level of quality) and we included in the meta-analysis studies which 
had a score higher or equal to 5 w1 w3 w5 w9-w11 w21 (Table 2). Cohort studies received a 
score between 0 and 7 (highest level of quality) and we included in the meta-analysis 
studies which had a score higher or equal to 6 w4 (Table 3) (see Quality assessment 
in appendix).  
 
Data extraction 
Included studies were independently reviewed by two authors (PYS and MC). 
Disparities were resolved by discussion.  
 
Study characteristics 
Each study was classified according to the design (either observational study or 
randomised controlled trials). Relevant data on the characteristics of hormone 
therapy (route of oestrogen administration, type of oestrogens, unopposed or 
opposed hormone regimen, duration of treatment) as well as the characteristics of 
venous thromboembolism (idiopathic or secondary, deep vein thrombosis or 
pulmonary embolism, ascertainment of venous thromboembolism) were extracted 
and used to provide an overall estimate. 
 
Statistical methods 
For each study, the most adjusted relative risks (RR) or odds ratios (OR) and their 
95% confidence interval (95% CI) were used. Homogeneity between the studies was 
analyzed using the ² and I² statistics 21 22. The results of homogenous studies were 
pooled and an overall estimate of relative risk was obtained from a fixed-effects 
model 23. Briefly, a weighted average of relative risks was calculated, with the 
weights being the inverse of variance of relative risk 24. For each study, the variance 
of relative risk was estimated from the 95% confidence interval. When between 
studies heterogeneity was detected, a random-effects model was used 23. Statistical 
analyses were performed using SAS statistical software (version 9.1, SAS Institute 
Inc, Cary, NC). 
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Results 
 
Characteristics of the studies 
General characteristics of subjects, sample size and types of treatment were studied 
for each observational study and randomized controlled trial. 
 
 Observational studies 
We selected seven case-control studies w1 w3 w5 w9-w11 w21 and one cohort study w4 
(figure 1 and appendix). Characteristics of included studies are summarized in the 
table 4.  
All the studies have investigated the risk of venous thromboembolism in relation to 
oral oestrogen use w1 w3-w5 w9-w11 w21 and four of them have evaluated the risk of 
venous thromboembolism in relation to transdermal route of oestrogen administration 
w1 w5 w10 w11. 
With regard to the characteristics of hormone therapy, women were treated by either 
17-oestradiol w1 w3 w5 w11 or conjugated equine oestrogens w1 w3-w5 w9 w11 w21 or 
esterified oestrogen w3 w9. Women were generally classified as current users if they 
had used hormone therapy at any time in the past 1 to 6 months before inclusion 
date.  
In most of the studies, the clinical endpoint was a first-time idiopathic venous 
thromboembolism (i.e. without provoking risk factors 25), either deep venous 
thrombosis or pulmonary embolism. The Nurses’ Health Study was restricted to first 
episode of either idiopathic or non idiopathic pulmonary embolism w4 and Smith 
included first-time idiopathic and non idiopathic venous thromboembolism w9. The 
clinical events were mostly validated by ultrasound (deep vein thrombosis) or lung 
scanning (pulmonary embolism).  
 
 Randomised controlled trials (Table 5) 
 Postmenopausal oEstrogen/Progestin Interventions (PEPI) w12  
PEPI was a multicenter, randomised, double-blind, placebo-controlled trial which 
examined the effects of hormone therapy on heart disease risk factors among 875 
healthy postmenopausal women. Intervention was placebo or 0.625 mg per day 
conjugated equine oestrogens alone or combined with either cyclic 
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medroxyprogesterone acetate or consecutive medroxyprogesterone acetate or cyclic 
micronised progesterone. During 3 years of follow-up, venous thromboembolism 
occurred in 4 women among pooled treated groups and none among the placebo 
group. 
 Heart and oEstrogen/progestin Replacement Study (HERS) w13 
HERS was the first clinical trial designed to investigate the effect of hormone therapy 
on coronary heart disease recurrence. Starting in 1993, HERS was a multi-centre 
randomised, double-blind, placebo-controlled trial that enrolled 2763 postmenopausal 
women (mean age 66.7 years) with an intact uterus. Intervention was 0.625 mg 
conjugated equine oestrogens plus 2.5 mg medroxyprogesterone acetate or placebo. 
Venous thromboembolism was used as a secondary outcome in HERS. Venous 
thromboembolism occurred in 34 women in the hormone therapy group and in 12 
women in the placebo group. 
 OEstrogen in Venous ThromboEmbolism Trial (EVTET) w14  
EVTET was a randomised double-blind trial, comparing 2 mg oestradiol plus 1 mg 
norethisterone acetate to placebo in postmenopausal women with previously 
documented venous thromboembolism. The study was stopped prematurely after a 
mean follow-up of 1 year and 4 months. More women experienced recurrent venous 
thromboembolism in the hormone therapy group than in the placebo group (8 and 1, 
respectively). 
 OEstrogen Replacement and Atherosclerosis trial (ERA) w15 
The ERA trial examined the effects of hormone therapy on the progression of 
coronary atherosclerosis in 309 postmenopausal women who had angiographically 
verified coronary heart disease. Women were randomly assigned to receive 
conjugated equine oestrogens (0.625 mg per day) alone or conjugated equine 
oestrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) 
or placebo. During 3.2 years of follow-up, venous thromboembolism occurred in 5 
women, 2 women and one woman respectively. 
 Women’s Oestrogen for Stroke Trial (WEST) w16 
WEST was started in 1993 as a randomised, placebo-controlled trial of hormone 
therapy for the secondary prevention of cerebrovascular disease. This trial was 
conducted in 664 postmenopausal women (mean age, 71 years) who had recently 
had an ischaemic stroke or transient ischaemic attack. Women were randomly 
assigned to receive either 1 mg of 17-oestradiol per day or a placebo. Women were 
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monitored for venous thromboembolism events. Venous thromboembolism occurred 
in 3 women in the hormone therapy group and in 4 women in the placebo group. 
 OEStrogen in the Prevention of ReInfarction Trial (ESPRIT) w17 
ESPRIT was set up in United Kingdom to assess the effect of unopposed oestradiol 
valerate on the risk of coronary heart disease in postmenopausal women who had 
survived their first myocardial infarction. The study was a randomised, blinded, 
placebo controlled, secondary prevention trial among 1017 women aged 50-69 
years. Women received either oestradiol valerate (2 mg per day) or placebo for 2 
years. In this secondary prevention trial after a first myocardial infraction, 2 women in 
the hormone therapy group and 1 in the placebo group experienced venous 
thromboembolism. 
 Women’s Health Initiative (WHI) w18 w19 w26 w27  
The WHI focuses on strategies which could potentially reduce the incidence of 
coronary heart disease, breast and colorectal cancer, and fractures in 
postmenopausal women. Between 1993 and 1998, the WHI enrolled 161 809 
postmenopausal women in the age range of 50 to 79 years into a set of clinical trials 
(trials of low-fat dietary pattern, calcium and vitamin D supplementation, and two 
trials of postmenopausal hormone therapy) and an observational study at 40 clinical 
centers in the United States. 
The oestrogen plus progestin component of the WHI was a randomised controlled 
primary prevention trial in which 16 608 postmenopausal women with an intact uterus 
were randomly assigned to receive conjugated equine oestrogens (0.625 mg per 
day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo w18. A total of 
218 venous thromboembolism was enumerated (151 in the hormone therapy group 
and 67 in the placebo group). 
The oestrogen alone component of the WHI was a randomised controlled primary 
prevention trial in which 10 739 postmenopausal women with prior hysterectomy 
were randomly assigned to receive conjugated equine oestrogens (0.625 mg per 
day) or placebo w19. Venous thromboembolism occurred in 167 oestrogen treated 
women and in 76 placebo treated ones.  
 The Women’s International Study of long Duration Oestrogen 
after Menopause (WISDOM) w20 
The WISDOM trial was a randomized, double blinded, placebo controlled trial, set up 
in United Kingdom, Australia and New Zealand to assess the long term risk and 
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benefits of hormone therapy in women aged 50 to 69 years without an arterial 
disease within the past 6 months before inclusion (n=5692). Women were randomly 
assigned to receive either conjugated equine oestrogens (0.625 mg per day) alone or 
conjugated equine oestrogens (0.625 mg per day) plus medroxyprogesterone 
acetate (2.5 mg per day) or placebo. It was planned to compare conjugated equine 
oestrogens plus medroxyprogesterone acetate with placebo and conjugated equine 
oestrogens plus medroxyprogesterone acetate with conjugated equine oestrogens 
alone. Ten years of treatment were been planned but WISDOM was prematurely 
closed following publication of the WHI results. After a mean follow-up of 11.9 
months, venous thromboembolism occurred in 22 women in the conjugated equine 
oestrogens plus medroxyprogesterone acetate group and in 3 women in the placebo 
group. Comparison of conjugated equine oestrogens plus medroxyprogesterone 
acetate versus conjugated equine oestrogens alone outcomes revealed no significant 
differences. 
 
Results of the meta-analysis 
Pooled risk of venous thromboembolism was assessed from eight observational 
studies and nine randomized controlled trials. From observational studies, the risk of 
venous thromboembolism was estimated by route of oestrogen administration. In 
addition, the risk of venous thromboembolism was estimated according to the 
characteristics of both treatment (type, duration) and venous thromboembolism 
(idiopathic or secondary, type of diagnostic). 
 
 Venous thromboembolism risk by characteristics of hormone therapy 
Figure 2 shows pooled OR of first-time venous thromboembolism in relation to 
hormone therapy use by study design and route of oestrogen administration. All but 
one observational studies w21 consistently reported an association between oral 
oestrogen use and an increased risk of venous thromboembolism w1 w3-w5 w9-w11. Four 
of them investigated the impact of transdermal oestrogen use on risk of first episode 
of venous thromboembolism w1 w5 w10 w11. Pooled OR (95% CI) for oral and 
transdermal oestrogen was 2.5 (1.9-3.4) and 1.2 (0.9-1.7), respectively. The upper 
95% CI for transdermal use (1.7) was lower than the lowest 95% CI for oral use (1.9). 
The association of venous thromboembolism with oral oestrogen use was confirmed 
by results from randomized controlled trials (pooled OR=2.1; 95%CI: 1.4-3.1). The 
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combined odds ratio from both trials and observational studies in oral estrogen users 
was 2.4 (1.9-3.0) and was higher than the summary risk among women using 
transdermal estrogen (p<0.001). No trials have investigated the effect of transdermal 
estrogen on the risk of venous thromboembolism. 
One study suggested that the type of oestrogen might be an important determinant of 
the risk of venous thromboembolism. In this study, conjugated equine oestrogen was 
associated with increased risk, whereas esterified oestrogen was not w9. 
Data on the risk of venous thromboembolism in past users of hormone therapy 
compared with never users were available in four observational studies w1 w4 w10 w11 
and showed that past use of hormone therapy was not associated with an increased 
risk of venous thromboembolism (pooled OR=1.2; 95%CI: 0.9-1.7) (Figure 3). 
The impact of unopposed and opposed oral oestrogen therapy on the risk of venous 
thromboembolism has been investigated in six observational studies w1 w3 w5 w9-w11. No 
significant difference in the risk of venous thromboembolism was observed between 
oral oestrogen alone and oral oestrogen/progestogen therapy (pooled OR=2.2; 
95%CI: 1.6-3.0 and pooled OR=2.6; 95% CI: 2.0-3.2, respectively).  
Finally, the risk of venous thromboembolism has been assessed according to the 
duration of treatment. Information on duration of oral oestrogen was available in only 
five case-control studies w1 w3 w5 w10 w11. Results from these studies showed that the 
risk of venous thromboembolism was significantly higher within the first year of 
treatment (pooled OR=4.0; 95% CI: 2.9-5.7 for a duration of hormone therapy less 
than one year and pooled OR=2.1; 95% CI: 1.3-3.8 for a duration of hormone therapy 
more than one year, p<0.05) (Figure 3).  
 
 Risk of venous thromboembolism by type of diagnosis 
When analysis was restricted to the first episode of idiopathic events w1 w3-w5 w10 w11 
w21, the risk of venous thromboembolism in relation to oral oestrogen use 
substantially increased (pooled OR=3.1; 95% CI: 2.3-4.1), whereas results for 
transdermal oestrogen use remained unchanged. 
Analysis by diagnosis of venous thromboembolism showed no significant difference 
in the risk of venous thromboembolism between deep vein thrombosis and 
pulmonary embolism in relation to oral oestrogen use. From observational studies, 
pooled OR (95% CI) was 2.8 (1.9-4.0) for deep vein thrombosis and 2.7 (1.1-2.5) for 
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pulmonary embolism. This result was confirmed by data from randomised controlled 
trials (data not shown). 
 
 Women at high risk for venous thromboembolism 
The impact of prothrombotic mutations 26 27 on the risk of venous thromboembolism, 
with or without hormone therapy, has been investigated in four case-control studies 
w28-w31 and in both WHI clinical trials w26 w27. Overall the presence of the Factor V 
Leiden mutation or prothrombin G20210A mutation increased the risk of venous 
thromboembolism more than 3-fold (pooled OR=3.3; 95%CI: 2.6-4.1). The 
combination of thrombogenic mutations and oral oestrogen use, especially 
conjugated equine oestrogen, with or without progestin, further enhanced the risk of 
venous thromboembolism (OR=8.0; 95% CI: 5.4-11.9) compared with women without 
mutations who did not use any treatment. However, in one study, there was no 
significant difference in the risk of venous thromboembolism between women with 
factor V Leiden mutation or prothrombin G20210A mutation using transdermal 
oestrogen and women with a mutation but not using oestrogen (OR= 4.4; 95%CI: 
2.0-9.9) w30 (Figure 4).  
The association of venous thromboembolism with hormone therapy in relation to 
elevated body-mass index has been investigated in both the WHI clinical trials w26 w27 
and in a case-control study w32. An elevated body-mass index (overweight or obesity) 
increased the risk of venous thromboembolism (pooled OR=2.6; 95%CI: 2.1-3.3). In 
addition, the combination of current oral oestrogen use and an increased body-mass 
index resulted in a further elevation of the risk of venous thromboembolism (pooled 
OR=5.4; 95%CI: 2.9-10.0). However, in one study, current use of transdermal 
oestrogen did not confer an additional risk on women with overweight or obesity w32 
(Figure 5). 
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Discussion 
 
Principal findings 
This meta-analysis of both observational studies and randomised controlled trials 
shows that current use of oral oestrogen increases two to three times the risk of 
venous thromboembolism. This elevation is higher within the first year of treatment 
and more pronounced for women at high thrombotic risk. Overall, with a baseline risk 
for venous thromboembolism of about 1 per 1000 women-years 28 29, an additional 
1.5 events per 1000 women each year would be expected. Combined analysis of 
observational studies shows no significant increase in the risk of venous 
thromboembolism among transdermal oestrogen users. 
 
Strengths of the study 
Previous reviews and meta-analysis regarding hormone therapy and risk of venous 
thromboembolism focused on oral oestrogen use and failed to take into account the 
route of oestrogen administration 7 11 13 15. This report provides the first quantitative 
assessment of the thrombotic risk among oral and transdermal oestrogen users 
separately. Moreover, the present meta-analysis investigated the impact of hormone 
therapy by route of oestrogen administration among women at high thrombotic risk. 
In two previous reviews 13 15, the risk of venous thromboembolism among oral 
oestrogen users who carried prothrombotic mutations was assessed from two case-
control studies w28-w29. We updated this meta-analysis by adding data from four 
studies w26 w27 w30 w31. With regard to women with overweight or obesity, our meta-
analysis is the first to show a substantial increase in the risk of venous 
thromboembolism among oral estrogen users with elevated body-mass index 
(overweight or obesity) w26 w27 w32.  
 
Weaknesses of the study 
In the present meta-analysis, assessment of the risk of venous thromboembolism 
among transdermal oestrogen was based on relatively few data w1 w5 w10 w11. 
Therefore, results should be interpreted with caution and further investigation of 
transdermal oestrogen is needed. Another limitation of the present report is the lack 
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of data on the impact of progestogens. Although this meta-analysis showed similar 
risk of venous thromboembolism comparing oral oestrogen alone and opposed oral 
oestrogen, progestogens have recently emerged as a determinant of the risk of 
venous thromboembolism. One study reported that the risk of venous 
thromboembolism was higher in users of opposed oral oestrogen than in users of oral 
oestrogen alone w10 and the risk of venous thromboembolism was higher in the WHI 
oestrogen/progestogen clinical trial w18 than in the WHI oestrogen alone clinical trial 
w19. In addition, among women recruited in the conjugated equine oestrogens plus 
medroxyprogesterone acetate versus conjugated equine oestrogens WISDOM trial, 
there was a suggestion in the opposed oestrogen therapy group of an increase in 
venous thromboembolism (RR=2.39; 95%CI: 0.62-9.24) w20. Finally, recent data from 
one case-control study showed that norpregnane derivatives might increase the risk 
of venous thromboembolism whereas there was no association of venous 
thromboembolism with micronised progesterone and pregnane derivatives w11. 
Our meta-analysis of both observational studies and randomised controlled trials 
showed heterogeneity between studies among oral oestrogen users. An important 
source of heterogeneity between trials may arise from differences in the duration of 
treatment. The WISDOM trial, which was closed after a median follow-up of 11.2 
months, reported an odds ratio for venous thromboembolism higher than those from 
other randomised controlled trials w20. When analysis was restricted to randomised 
trials with a longer follow-up, heterogeneity between studies disappeared. 
Explanations for heterogeneity between observational studies include differences in 
the type of venous thrombotic event. Two studies included women with non-idiopathic 
venous thromboembolism w4 w9. If analysis was restricted to idiopathic venous 
thromboembolism, heterogeneity between observational studies disappeared. There 
were also differences in results by study design. The association of venous 
thromboembolism with oral oestrogen use was lower in randomized controlled trials 
than in observational studies. This difference could be explained by inclusion of 
procedure-related venous thromboembolism in WHI trials, as well as the high degree 
of nonadherence to study medication in randomized controlled trials, resulting in an 
underestimation of hormone effects in randomized controlled trials. 
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Biological explanations for results 
Biological evidence lends support to the difference in the risk of venous 
thromboembolism between oral and transdermal oestrogen. Oral oestrogen 
administration results in a hepatic first-pass effect and may impair the balance 
between procoagulant factors and antithrombotic mechanisms 30. Oral, but not 
transdermal, oestrogen increases plasma concentrations of prothrombin fragment 
1+2 31 32, which is a marker for in-vivo thrombin generation, and increases the 
fibrinolytic potential in postmenopausal women. A lower antithrombin concentration 
has also been shown in women using oral oestrogen but not in those using 
transdermal oestrogens 33. In addition, an acquired resistance to activated protein C 
has been demonstrated in users of oral oestrogen 34 35 but two randomised trials 
recently indicated that these results did not apply to users of transdermal oestrogen 
32 36. Thus, transdermal oestrogen appears to have little or no effect on haemostasis. 
  
Clinical implications 
The findings of the present meta-analysis of studies by route of estrogen 
administration may have important clinical implications. Pulmonary embolism 
accounts for about one third of the excess incidence of potentially fatal events due to 
long-term hormone therapy 4. Therefore, the risk of venous thromboembolism is an 
important determinant of the benefit/risk profile of hormone therapy, and differences 
in the risk of venous thromboembolism between types of hormone therapy may have 
important clinical implications. In addition, since recent guidelines recommend that 
women are prescribed the lowest effective dose of hormone therapy for the shortest 
time possible 37, pulmonary embolism becomes a main adverse effect due to oral 
oestrogen therapy within the first year of treatment. By contrast, there is little increase 
risk of stroke and breast cancer within the first year of treatment. Therefore, reducing 
venous thromboembolism risk by transdermal oestrogen use could improve the 
benefit/risk profile of hormone therapy, especially among women at high risk of 
venous thromboembolism (e.g. known prothrombotic mutation, elevated body-mass 
index).  
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Future research 
Future randomized trials of oral versus transdermal oestrogen will clarify this 
apparent lower risk. Clinical research should continue into genetic factors influencing 
the risk associated with hormone therapy, different oestrogen and progestogen 
formulations, different modes of delivery, lower-dose options and alternative 
regimens (e.g. selective oestrogen receptor modulators, phytooestrogens). Such 
research will assist patients and clinicians in making treatment decisions on the basis 
of an individual’s benefits and risks 38. 
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“What this study add” box 
What is already known on this topic 
Hormone therapy improves the quality of life but it is known to increase the risk of 
venous thromboembolism. 
What this study adds 
Transdermal oestrogen decreases the risk of venous thromboembolism when 
compared to oral oestrogen and it appears safe with respect to thrombotic risk. 
Women with prothrombotic mutations or elevated body-mass index are at high risk of 
venous thromboembolism and should be discouraged from using oral oestrogen 
therapy. 
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Table1- Quality assessment of included randomised controlled trials (Appropriate=1 / No information or no appropriate=0) 
 
 
Study, years Randomisation  
Double-
blinding 
Dropout and 
withdrawals 
Generation of 
random numbers 
Allocation 
concealment 
Score (0-5) 
       
PEPI w12,1995 Yes Yes 
3.0% withdrawal 
and dropout 
Computer generated 
block randomisation 
Active drug and 
placebo prepared in 
identical forms 
5 
HERS w13, 1998  Yes Yes 
0% dropout 
2.1% withdrawal 
Computer generated 
random numbers 
Active drug and 
placebo prepared in 
identical forms 
5 
EVTET w14, 2000  Yes Yes 
23.6% dropout or 
withdrawal 
Computer generated 
block randomisation 
Active drug and 
placebo prepared in 
identical forms 
5 
ERA w15, 2000 Yes Yes 
14.0% dropout 
4.0% withdrawal 
Permuted block 
randomisation 
Each women 
received two tablets 
(active treatment 
and placebo tablets 
or 2 placebo tablets) 
5 
WEST w16, 2001  Yes Yes 
0% dropout 
1.4% withdrawal 
Computer generated 
block randomisation 
? 4 
ESPRIT w17, 2002  Yes Yes ? 
Computer generated 
block randomisation 
Active drug and 
placebo prepared in 
identical forms 
4 
WHI I w18, 2002  Yes Yes 3.5% dropout 
Permuted block 
randomisation 
Active drug and 
placebo prepared in 
identical forms 
5 
WHI II w19, 2004  Yes Yes 
2.2% dropout 
3.0% withdrawal 
Permuted block 
randomisation 
Active drug and 
placebo prepared in 
identical forms 
5 
WISDOM w20, 2007 Yes Yes 
0.01% dropout 
13.2% withdrawal 
Computer generated 
block randomisation 
Active drug and 
placebo prepared in 
identical forms 
5 
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Table 2- Quality assessment of included case/control studies (Yes=1 / No=0) 
 
Author or Study, 
year 
Appropriate inclusion 
and exclusion criteria 
applied equally to cases 
and controls 
Only first episode 
of venous 
thromboembolism 
Objective 
diagnostic 
procedure 
Adequate 
assessment of 
menopausal 
status 
Accurate assessment 
of HT including the 
route of oestrogen 
administration 
Adequate analysis 
and controlling for 
confusion 
(adjustment) 
Score 
(0-6) 
        
Boston CDSP 
w21, 1974 
Yes Yes No Yes Yes Yes 5 
Daly w1, 1996 Yes Yes No Yes Yes Yes 5 
Jick w3, 1996  Yes Yes Yes Yes Yes Yes 6 
Perez-Gutthann 
w5, 1997  
Yes Yes No Yes Yes Yes 5 
Smith w9, 2004  Yes Yes Yes Yes Yes Yes 6 
Douketis w10, 
2005 
Yes Yes Yes Yes Yes Yes 6 
ESTHER Study 
w11, 2007 
Yes Yes Yes Yes Yes Yes 6 
 
Table 3- Quality assessment of included cohort studies (Yes =1 / No =0) 
 
Author or Study, 
year 
Appropriate 
method of subject 
selection 
Only first episode 
of venous 
thromboembolism 
Objectives 
diagnostic 
procedure 
Adequate 
assessment of 
menopausal 
status 
Accurate 
assessment of 
HT including 
the route of 
oestrogen 
administration 
Overall low 
loss of follow-
up 
Adequate 
analysis and 
controlling for 
confusion 
(adjustment) 
Score 
(0-7) 
         
Nurses’ Health 
Study w4, 1996  
Yes Yes Yes Yes Yes Yes Yes 7 
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Table 4- Characteristics of included observational studies  
 
Author or Study, 
year 
Route of 
oestrogen 
administration 
Clinical 
endpoint 
Oestrogen 
type 
Current 
users 
definition* 
Exposed 
cases (n) 
Adjusted risk 
ratio of VTE 
(95 % CI) 
       
Boston CDSP w21, 
1974 
Oral 
1st episode of 
idiopathic VTE 
Mainly 
CEE 
NA 3 1.9 (1.4-7.8) 
       
Daly w1, 1996  
Oral 1st episode of 
idiopathic VTE 
E2 / CEO 
Less than 1 
37 4.6 (2.1-10.1) 
Transdermal E2 5 2.0 (0.5-7.6) 
       
Jick w3, 1996  Oral 
1st episode of 
idiopathic VTE 
CEE / EO Less than 6 21 3.6 (1.6-7.8) 
       
Nurses’ Health Study 
w4, 1996  
Oral 
1st episode of 
PE 
Mainly 
CEE 
NA 68 2.1 (1.2-3.8) 
       
Perez-Gutthann w5, 
1997  
Oral 
1st episode of 
idiopathic VTE 
E2 / CEO 
Less than 6 
20 2.1 (1.3-3.6) 
Transdermal E2 7 2.1 (0.9-4.6) 
       
Smith w9, 2004  Oral 
1st episode of 
VTE 
CEO 
NA 
121 1.7 (1.2-2.2) 
EO 86 0.9 (0.7-1.2) 
       
Douketis w10], 2005 
Oral 1st episode of 
idiopathic VTE 
NA 
Less than 1 
36 1.9 (1.2-3.2) 
Transdermal NA 3 0.8 (0.3- 2.8) 
       
ESTHER Study  w11, 
2007 
Oral 
1st episode of 
idiopathic VTE 
E2 / CEO 
Less than 3 
57 4.5 (2.6-7.5) 
Transdermal E2 67 1.1 (0.8-1.7) 
       
* Time duration between oestrogen use and VTE to be considered as current users (months) 
# 90% CI 
95 % CI: 95 % confidence interval 
VTE: venous thromboembolism 
PE: pulmonary embolism 
NA: not available 
E2: oestradiol or oestradiol valerate 
CEO: conjugated equine oestrogen 
EO: esterified oestrogen 
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Table 5- Characteristics of included randomised controlled trials 
 
Study, years 
Total 
number of 
subjects * 
Clinical 
background  
Duration of the 
trial (years) 
Number of 
events 
HT/placebo 
Adjusted risk 
ratio of VTE  
(95 % CI) 
      
PEPI w12,1995 847 “Healthy” 3 4/0 § 1.9 (0.1-36.5) $ # 
HERS w13, 1998  2763 History of CHD 4.1 34/12 2.9 (1.5-5.6) 
EVTET w14, 2000  140 History of VTE 1.3 8/1 7.8 (1.0-60.5) 
ERA w15, 2000 309 History of CHD 3.2 7/1 £ 3.6 (0.5-28.9) $ 
WEST w16, 2001  664 History of stroke 2.8 3/4 0.8 (0.2-3.4) 
ESPRIT w17, 2002  1017 History of CHD 2 5/4 1.2 (0.3-4.6) 
WHI I w18, 2002  16608 “Healthy” 5.2 151/67 2.1 (1.6-2.7) 
WHI II w19, 2004  10739 “Healthy” 7 77/54 1.3 (1.0-1.8) 
WISDOM w20, 2007 5692 
Possible history of 
arterial disease  
0.99 22/3 7.4 (2.2-24.6) 
      
* Approximately equal number in placebo and active treatment group except in PEPI and 
ERA trials 
§ HT: n=682 Placebo: n=165 
$ Risk was calculated from data reported in the study 
# To estimate the RR, number of events in placebo group was considered equal to 0.5 
£ HT: n=204 Placebo: n=105 
CHD : coronary heart disease 
95 % CI : 95 % confidence interval 
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Legend of figures 
 
Figure 1. 
Results of literature search for randomized controlled trials and observational studies 
of hormone therapy that reported venous thromboembolism. 
 
Figure 2. 
Risk of first episode of venous thromboembolism by study design and route of 
oestrogen administration. Values are adjusted odds ratios (95% confidence interval). 
(NHS: Nurses’ Health Study; Trans: transdermal; RCTs: randomised controlled 
trials). 
 
Figure 3. 
Risk of venous thromboembolism by characteristics of hormone therapy among 
users of oral oestrogen. Values are odds ratios (95% confidence interval). 
(O: oestrogen; O+P: oestrogen and progestogen; HT: hormone therapy). 
 
Figure 4. 
Risks of venous thromboembolism among hormone therapy users by route of 
oestrogen administration and presence of one of two prothrombotic mutations (Factor 
V Leiden mutation and/or prothrombin G20210A mutation). Values are odds ratios 
(95% confidence intervals) 
(O : oestrogen). 
 
Figure 5. 
Risks of venous thromboembolism among hormone therapy users by route of 
oestrogen administration and presence of an elevated body-mass index (overweight 
or obesity). Values are odds ratios (95% confidence intervals) 
(O : oestrogen). 
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Articles identified by key words using 
MEDLINE database (n=1890)
Articles selected on titles and abstracts 
(n=111)
24 potentially appropriate studies
15 observational studies9 Randomised
controlled trials
8 observational studies 
included in meta-analyse
9 randomised controlled trials 
included in meta-analysis
•Articles not in English
•Not related to the topic
•On contraception
•Biological studies
•Reviews
•Did not assess VTE risk
7 excluded studies because
•Not only first VTE  (n=4)
•Without objective diagnostic 
procedures (n=3)
•No adequate assessment of 
postmenopausal status (n=6)
•No information on the route of 
estrogen administration (n=5)*
* n > 7 because excluded studies have more than one defect 
(low score of quality)
Figure 1
Review BMJ   Final version R4  
29/34 
 
Review BMJ   Final version R4  
30/34 
 
Review BMJ   Final version R4  
31/34 
1 10 100
Boston CDSP, 1974 1.9 [0.4-7.8]
Daly, 1996 4.6 [2.1-10.1]
Jick, 1996 3.6 [1.6-7.8]
NHS, 1996 2.4 [1.2-4.6]
Perez-Gutthann, 1997 2.1 [1.3-3.6]
Smith, 2004 1.7 [1.2-2.2]
Douketis, 2005 1.9 [1.2-3.2]
ESTHER, 2007 4.5 [2.6-7.5]
Pooled OR 2.5 [1.9-3.4]
Test for homogeneity: ²=14.99 (p=0.03), I²=53.3 %
Daly, 1996 2.0 [0.5-7.6]
Perez-Gutthann, 1997 2.1 [0.9-4.6]
Douketis, 2004 0.8 [0.3-2.8] 
ESTHER, 2007 1.1 [0.8-1.7]
Pooled OR 1.2 [0.9-1.7]
Test for homogeneity: ²=2.92 (p=0.40), I²=0 %
PEPI, 1995 1.9 [0.1-36.5]
HERS, 1998 2.9 [1.5-5.6)
EVTET, 2000 7.8 [1.0-60.5]
ERA, 2000 3.6 [0.5-28.9]
WEST, 2001 0.8 [0.2-3.4]
ESPRIT, 2002 1.2 [0.3-4.6]
WHI I, 2002 2.1 [1.6-2.7]
WHI II, 2004 1.3 [1.0-1.8]
WISDOM, 2007 7.4 [2.2-24.6]
Pooled OR 2.1 [1.4-3.1]
Test for homogeneity: ²=17.01 (p=0.03), I²=58.9 %
Figure 2
Design             Oestrogen Authors or Study,     OR [95% CI]                                               
Oral
Oral
Trans
Observational
studies
RCTs
route years
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1 10
Figure 3
Never use 1
Past use 1.2 (0.9-1.7)*
Test for homogeneity: ²=1.03 (p=0.79), I²=0 %
Current use of O alone 2.2 (1.6-3.0)#
Test for homogeneity: ²=6.16 (p=0.29), I²=18.8 %
Current use of O+P 2.6 (2.0-3.2)#
Test for homogeneity: ²=5.27 (p=0.38), I²=5.2 %
Duration of HT < 1 year 4.0 (2.9-5.7)$
Test for homogeneity: ²=5.23 (p=0.26), I²=23.6 %
Duration of HT > 1 year 2.1 (1.3-3.8)$
Test for homogeneity: ²=16.3 (p.002), I²=75.2 %
Characteristics of HT OR (95% CI)
Derived from :  * 4 observational studies [w1 w4 w10 w11]
# 6 observational studies [w1 w3 w5 w9-w11] 
$ 5 observational studies [w1 w3 w5 w10 w11] 
p=0.45
p=0.046
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1 10 100
Rosendaal, 2001 3.8 [1.7-8.5]
Herrington, 2002 3.3 [1.1-9.8]
ESTHER, 2005 3.9 [2.6-5.9]
WHI I, 2004 1.6 [0.5-5.4]
WHI II, 2006 2.2 [0.6-8.6]
Smith, 2006 3.1 [2.2-4.1]
Pooled OR 3.3 [2.6-4.1]
Test for homogeneity: ²=2.67 (p=0.75), I²=0 %
Rosendaal, 2003 11.0 [2.7-44.0]
Herrington, 2003 14.1 [2.7-72.4]
ESTHER, 2005 25.5 [6.9-95.0]
WHI I, 2004 5.2 [2.8-9.8]
WHI II, 2006 3.5 [0.2-11.1]
Smith, 2006 9.1 [4.5-18.2]
Pooled OR 8.0 [5.4-11.9]
Test for homogeneity: ²=6.29 (p=0.28), I²=20.5 %
ESTHER, 2005 4.4 [2.0-9.9]
Figure 4
Characteristics Authors or Study,      OR [95% CI] 
One of
prothrombotic 
mutation
One of
prothrombotic 
mutation and
oral O
One of
prothrombotic 
mutation and
transdermal O
derived from [w26-w31] 
years
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1 10 100
ESTHER, 2006 2.9 [2.1-4.0]
WHI I, 2004 2.2 [1.4-3.5]
WHI II, 2006 2.6 [1.5-4.4]
Pooled OR 2.6 [2.1-3.3]
Test for homogeneity: ²=0.94 (p=0.63), I²=0 %
ESTHER, 2006 13.1 [5.5-31.1]
WHI I, 2004 4.7 [3.1-7.1]
WHI II, 2006 3.3 [1.9-5.6]
Pooled OR 5.4 [2.9-10.0]
Test for homogeneity: ²=7.01 (p=0.03), I²=71.5 %
ESTHER, 2006 3.5 [2.0-6.2]
Figure 5
Characteristics Authors or Study,      OR [95% CI] 
BMI>25 kg/m²
BMI>25 kg/m²
and oral O
BMI>25 kg/m² and
transdermal O
derived from [w26 w27 w32] 
years
 
